CG Oncology, Inc. (CGON)
NASDAQ:CGON
Want to see CGON full AI Analyst Report?
Top Page
CG Oncology, Inc.
(NASDAQ:CGON)
Select Model
Select Model
Rating:50Neutral
Price Target:
$54.00
▼(-26.46% Downside)
Action:Reiterated
Date:06/09/26
Overall score is held back primarily by heavy losses and significant cash burn despite strong capitalization. Technically, the stock is in a downtrend (below key moving averages with negative MACD), though it appears oversold. Valuation offers limited support due to negative earnings, while recent corporate events provide only a modest positive offset.
Positive Factors
Very low leverage / strong equity base
A very large equity base and negligible debt provide durable financial flexibility to fund multi-year clinical programs, R&D and potential commercialization. This reduces refinancing and bankruptcy risk, supports strategic optionality (partnerships, acquisitions, trial spend) as milestones are pursued.
Negative Factors
High and rising cash burn
Substantial negative operating and free cash flows that have widened year-over-year create persistent funding pressure. Continued burn requires external financing or rapid revenue ramp, increasing dilution risk and placing strategic constraints on trial pacing and commercialization investments over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage / strong equity base
A very large equity base and negligible debt provide durable financial flexibility to fund multi-year clinical programs, R&D and potential commercialization. This reduces refinancing and bankruptcy risk, supports strategic optionality (partnerships, acquisitions, trial spend) as milestones are pursued.
Read all positive factors
CG Oncology, Inc. (CGON) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.08B
Dividend YieldN/A
Average Volume (3M)934.23K
Price to Earnings (P/E)―
Beta (1Y)1.66
Revenue Growth666.01%
EPS Growth-69.02%
CountryUS
Employees113
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.34
Shares Outstanding88,202,480
10 Day Avg. Volume948,100
30 Day Avg. Volume934,232
Financial Highlights & Ratios
PEG Ratio-0.42
Price to Book (P/B)4.26
Price to Sales (P/S)794.47
P/FCF Ratio-24.23
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue1.08K
Enterprise Value/Gross Profit-2.30K
Enterprise Value/Ebitda-29.64
Forecast
1Y Price Target
$92.50Price Target Upside25.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-2.72
Revenue Forecast (FY)$11.76M
CG Oncology, Inc. Business Overview & Revenue Model
Company Description
CG Oncology Inc. is a biotechnology company in the clinical development stage, committed to advancing and bringing to market an innovative, bladder-sparing core treatment for individuals diagnosed with bladder cancer. Their principal drug candidat...
How the Company Makes Money
As a clinical-stage company, CG Oncology does not have publicly established, recurring commercial product revenue. Its funding has primarily come from external financing such as equity issuances (including proceeds from its IPO and follow-on offer...
CG Oncology, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
86
Very Positive
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.07M | 4.04M | 1.14M | 204.00K | 191.00K | 10.36M |
| Gross Profit | -2.38M | -607.00K | 1.14M | 204.00K | 176.00K | 10.35M |
| EBITDA | -184.48M | -159.55M | -88.01M | -48.59M | -35.43M | -12.38M |
| Net Income | -186.75M | -161.00M | -88.04M | -48.61M | -35.44M | -12.84M |
Balance Sheet | ||||||
| Total Assets | 1.14B | 791.59M | 754.80M | 199.30M | 147.75M | 58.69M |
| Cash, Cash Equivalents and Short-Term Investments | 1.08B | 742.15M | 742.00M | 187.67M | 143.48M | 53.61M |
| Total Debt | 7.58M | 7.02M | 238.00K | 1.03M | 15.94M | 15.13M |
| Total Liabilities | 43.48M | 38.99M | 21.42M | 14.51M | 22.57M | 18.44M |
| Stockholders Equity | 1.09B | 752.60M | 733.38M | 184.79M | 125.18M | 40.25M |
Cash Flow | ||||||
| Free Cash Flow | -160.43M | -132.48M | -78.95M | -45.68M | -29.82M | -13.75M |
| Operating Cash Flow | -160.01M | -132.35M | -78.71M | -45.68M | -29.80M | -13.65M |
| Investing Cash Flow | -393.90M | -245.82M | -300.76M | -121.19M | -55.35M | -97.00K |
| Financing Cash Flow | 546.14M | 153.59M | 628.28M | 87.00M | 119.69M | 15.45M |
CG Oncology, Inc. Technical Analysis
Neutral
73.43
Price Trends
65.09
Negative
61.92
Negative
51.20
Positive
Market Momentum
-2.64
Negative
47.49
Neutral
50.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CGON, the sentiment is Neutral. The current price of 73.43 is above the 20-day moving average (MA) of 59.73, above the 50-day MA of 65.09, and above the 200-day MA of 51.20, indicating a neutral trend. The MACD of -2.64 indicates Negative momentum. The RSI at 47.49 is Neutral, neither overbought nor oversold. The STOCH value of 50.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CGON.
CG Oncology, Inc. Risk Analysis
CG Oncology, Inc. disclosed 82 risk factors in its most recent earnings report. CG Oncology, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
CG Oncology, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $3.08B | -1,327.41 | -1.41% | ― | 95.29% | 98.21% | |
55 Neutral | $2.74B | ― | -13.96% | ― | 3118.14% | 55.95% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $5.08B | ― | -23.33% | ― | 666.01% | -69.02% | |
48 Neutral | $3.03B | -46.09 | -5.89% | ― | 157.97% | 86.11% | |
47 Neutral | $2.60B | -10.83 | -36.95% | ― | ― | -68.57% | |
45 Neutral | $5.57B | ― | -83.29% | ― | ― | 0.01% |
* Healthcare Sector Average
CGON
CG Oncology, Inc.
59.56
33.70
130.32%
COGT
Cogent Biosciences
33.10
26.02
367.51%
IDYA
IDEAYA Biosciences
28.98
6.80
30.66%
ARQT
Arcutis Biotherapeutics
24.38
10.95
81.53%
BEAM
Beam Therapeutics
29.03
11.97
70.16%
IRON
Disc Medicine
67.99
14.28
26.59%
CG Oncology, Inc. Corporate Events
Executive/Board ChangesShareholder Meetings
CG Oncology Shareholders Back Directors and Governance Proposals
Positive
Jun 8, 2026
On June 4, 2026, CG Oncology, Inc. held its 2026 Annual Meeting of Stockholders, at which shareholders elected Christina Rossi and Victor Tong, Jr. as Class II directors to serve until the 2029 annual meeting, and ratified Ernst Young LLP as the ...
Business Operations and StrategyExecutive/Board Changes
CG Oncology Reshapes Executive Team Amid Leadership Transition
Neutral
May 26, 2026
On May 20, 2026, CG Oncology, Inc. announced that President and Chief Operating Officer Ambaw Bellete agreed to separate from the company, effective June 30, 2026. The company plans to provide severance benefits under his existing employment agree...
Business Operations and StrategyExecutive/Board Changes
CG Oncology Appoints Veteran Jim DeTore as Chief Financial Officer
Positive
Apr 13, 2026
On April 13, 2026, CG Oncology, Inc. appointed veteran biotech finance executive Jim DeTore as its Chief Financial Officer, formalizing his role after serving as Interim Principal Financial and Accounting Officer since November 2025. DeTore brings...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.